Published in Urol Res on November 13, 2004
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing. PLoS One (2014) 0.93
Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci (2010) 0.88
Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Dis Model Mech (2012) 0.88
Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. Oncotarget (2015) 0.80
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget (2014) 0.80
Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagn Pathol (2014) 0.79
Current animal models of bladder cancer: Awareness of translatability (Review). Exp Ther Med (2014) 0.78
Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens. Urol Oncol (2013) 0.78
Investigation of the association between mitochondrial DNA and p53 gene mutations in transitional cell carcinoma of the bladder. Oncol Lett (2016) 0.75
The role of WNT signalling in urothelial cell carcinoma. Ann R Coll Surg Engl (2015) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Cancer. p53, guardian of the genome. Nature (1992) 16.36
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 7.34
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (1995) 6.01
Tumor angiogenesis. Adv Cancer Res (1985) 5.66
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Structural evidence for the authenticity of the human retinoblastoma gene. Science (1987) 4.67
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res (1995) 4.28
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science (1986) 3.74
Identification of p53 gene mutations in bladder cancers and urine samples. Science (1991) 3.68
Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med (1996) 3.64
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Expression and characterization of the human c-myc DNA-binding protein. Mol Cell Biol (1985) 3.24
Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta (1990) 3.18
MDM2--master regulator of the p53 tumor suppressor protein. Gene (2000) 2.92
Regional assignment of genes for human esterase D and retinoblastoma to chromosome band 13q14. Science (1980) 2.72
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol (1995) 2.62
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A (1991) 1.94
Angiogenesis and angiogenesis inhibition: an overview. EXS (1997) 1.94
Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res (1994) 1.86
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol (1993) 1.85
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res (1998) 1.65
HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J (1989) 1.63
Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol (1998) 1.60
The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Trends Biochem Sci (1998) 1.59
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer (1994) 1.58
Ureteroscopy: current practice and long-term complications. J Urol (1997) 1.56
Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer (1994) 1.55
Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst (1994) 1.52
Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst (1992) 1.51
Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene (1997) 1.47
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst (1997) 1.45
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res (1995) 1.39
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res (1997) 1.35
The pathophysiology of angiogenesis. Crit Rev Oral Biol Med (1995) 1.34
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol (1999) 1.30
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet (1995) 1.30
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res (1997) 1.24
Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol (1995) 1.22
Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics (1998) 1.21
The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int (1999) 1.21
Molecular mediators of angiogenesis in bladder cancer. Cancer Res (1998) 1.20
Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene (1995) 1.14
Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst (1993) 1.12
Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol (1994) 1.12
How and when do tumor cells metastasize? Crit Rev Oncog (1993) 1.10
Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res (1990) 1.09
Role of myc amplification and overexpression in cell growth, differentiation and death. Semin Cancer Biol (1993) 1.08
C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res (1995) 1.06
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res (1998) 1.06
Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer (1993) 1.06
Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol (1996) 1.05
Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res (1996) 1.04
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol (1999) 1.04
Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. Mol Biol Cell (1998) 1.03
Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene (1994) 1.01
Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res (1991) 1.01
Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res (1996) 1.01
Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol (1997) 1.01
Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol (1996) 1.00
The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer (1994) 0.99
Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol (1991) 0.97
An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer (1992) 0.97
Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med (1981) 0.96
What is the role of angiogenesis in metastasis from cutaneous melanoma? Eur J Cancer Clin Oncol (1987) 0.95
Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res (1996) 0.95
Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (1996) 0.95
Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst (1995) 0.94
Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene (1996) 0.92
Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Br J Cancer (1996) 0.91
Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev (1999) 0.90
Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol Res (1992) 0.90
Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest (1995) 0.88
Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinog (1995) 0.88
Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer (1993) 0.88
Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res (1990) 0.87
The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev (1998) 0.87
Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol (1995) 0.87
Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol (1993) 0.86
Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol (1996) 0.85
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Urinary diversion. Urology (2007) 2.65
Benign retroperitoneal schwannoma: a case series and review of the literature. Urology (2003) 2.62
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol (2004) 2.50
Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol (2006) 2.01
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am (2005) 1.74
Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol (2007) 1.60
Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int (2013) 1.59
Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol (2008) 1.58
Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer (2005) 1.55
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
Impact of robotic training on surgical and pathologic outcomes during robot-assisted laparoscopic radical prostatectomy. Urology (2010) 1.49
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol (2005) 1.45
Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer. Urology (2010) 1.42
Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol (2007) 1.41
Pathologic guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. Rev Urol (2006) 1.40
Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer (2005) 1.28
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol (2006) 1.16
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol (2005) 1.13
Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU Int (2011) 1.10
A critical analysis of perioperative mortality from radical cystectomy. J Urol (2006) 1.10
The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol (2004) 1.10
Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guérin-induced bladder contractures. Urology (2005) 1.06
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Pubovaginal slings for stress urinary incontinence following radical cystectomy and orthotopic neobladder reconstruction in women. J Urol (2004) 1.03
Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol (2007) 1.00
Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol (2002) 1.00
Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol (2009) 0.96
Surgical benchmarks for the treatment of invasive bladder cancer. Urol Oncol (2007) 0.91
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol (2015) 0.91
Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer (2003) 0.91
The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World J Urol (2008) 0.90
Rapid implementation of a robot-assisted prostatectomy program in a large health maintenance organization setting. J Endourol (2010) 0.88
Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J Urol (2004) 0.88
Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther (2005) 0.88
Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol (2004) 0.85
Training the urologic oncologist of the future: where are the challenges? Urol Oncol (2009) 0.84
The prognostic and staging value of lymph node dissection in the treatment of invasive bladder cancer. Nat Clin Pract Urol (2006) 0.83
Decision tree for laparoscopic partial nephrectomy versus laparoscopic renal cryoablation for small renal masses. J Endourol (2009) 0.83
Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther (2006) 0.82
New molecular markers for bladder cancer detection. Curr Opin Urol (2004) 0.82
Angiomyolipoma with vena caval extension. Urology (2002) 0.82
T-pouch: a new valve design for a continent ileostomy. Dis Colon Rectum (2002) 0.82
Urethral foreign body management: a case report. ScientificWorldJournal (2004) 0.82
Lymphadenectomy in bladder cancer: a review. Urol Int (2007) 0.82
The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer. Urol Oncol (2004) 0.80
Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer. Expert Rev Anticancer Ther (2008) 0.80
Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy. Cancer Lett (2013) 0.80
Indications for early cystectomy. Urology (2003) 0.80
Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol (2003) 0.80
Superficial bladder cancer: part 2. Management. Expert Rev Anticancer Ther (2007) 0.78
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol (2008) 0.78
Choosing earlier therapy for muscle-invasive bladder cancer. Rev Urol (2005) 0.78
Outcomes of patients with clinical CIS-only disease treated with radical cystectomy. World J Urol (2008) 0.77
Molecular prognostic factors in bladder cancer. BJU Int (2005) 0.77
Outcomes of radical cystectomy. BJU Int (2008) 0.77
Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle: an update. Urol Oncol (2005) 0.76
Comparison of extraperitoneal and intraperitoneal augmentation enterocystoplasty for neurogenic bladder in spinal cord injury patients. World J Urol (2008) 0.76
The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer. Expert Rev Anticancer Ther (2004) 0.76
Black men have lower rates than white men of biochemical failure with primary androgen-deprivation therapy. Perm J (2011) 0.75
Achieving proficiency with robot-assisted radical prostatectomy: Laparoscopic-trained versus robotics-trained surgeons. Can Urol Assoc J (2013) 0.75
Which treatment should patients with high-risk T1G3 bladder cancer receive? Nat Clin Pract Urol (2008) 0.75
Surgical considerations for elderly urologic oncology patients. Urol Oncol (2009) 0.75
Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle. Expert Rev Anticancer Ther (2005) 0.75
The treatment of patients with bladder cancer: let's not forget the past! J Urol (2005) 0.75
Hemi-T pouch modification for pediatric urinary diversion. J Urol (2003) 0.75
Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability. Urology (2005) 0.75